comparemela.com

Latest Breaking News On - George barth geller distinguished professor for research - Page 1 : comparemela.com

AEGEAN Subgroup Analysis Fails to Demonstrate Clear Benefit With Perioperative Durvalumab Plus Chemo in EGFR+ NSCLC

David Harpole, MD, discusses key data from the first interim analysis of the AEGEAN trial, changes to the adjuvant treatment landscape that inspired the subgroup analysis of patients with EGFR mutations excluded from the intention-to-treat population, and more.

Dr Harpole on the Design of an Exploratory Analysis of the AEGEAN Trial in NSCLC

David Harpole, MD, discusses on the rationale and design of an exploratory analysis of the phase 3 AEGEAN trial in patients with EGFR-mutated non–small cell lung cancer, which he presented at the 2023 IASLC World Conference on Lung Cancer.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.